pulmonary disorders
Pneumocystis jirovecii Pneumonia
Prevention of Pneumocystis jirovecii Pneumonia
HIV-infected patients who have hadP. jiroveciipneumonia or who have a CD4+ T cell count<200/microL should receive prophylaxis with TMP/SMX 160/800 mg orally once a day or TMP/SMX 80/400 mg orally once a day; if this regimen is not tolerated,dapsone100 mg orally once a day (or 50 mg orally twice a day) or aerosolizedpentamidine300 mg once a month can be used. These prophylactic regimens are also indicated for many non–HIV-infected patients at risk ofP. jiroveciipneumonia. 